Charles River Laboratories International (NYSE:CRL – Get Free Report) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 11.150-11.450 for the period, compared to the consensus earnings per share estimate of 11.090. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.8 billion.
Analysts Set New Price Targets
Several research firms recently issued reports on CRL. Morgan Stanley upped their price objective on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their price target for the company from $180.00 to $310.00 in a research note on Thursday. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Finally, Mizuho increased their target price on Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $244.19.
View Our Latest Research Report on CRL
Charles River Laboratories International Trading Up 1.0%
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $977.20 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts anticipate that Charles River Laboratories International will post 11.05 earnings per share for the current year.
Insider Activity
In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.
More Charles River Laboratories International News
Here are the key news stories impacting Charles River Laboratories International this week:
- Positive Sentiment: JPMorgan upgraded CRL to “overweight” and raised its price target to $310 from $180, implying additional upside and signaling increased confidence in the company’s earnings recovery and demand outlook. Benzinga
- Positive Sentiment: Second-quarter results exceeded Wall Street expectations: adjusted earnings were $3.02 per share versus the $2.77 consensus, while revenue of approximately $1.0 billion topped estimates of $977.2 million. The earnings beat helped support the stock’s advance. Charles River Laboratories Q2 Earnings and Revenues Surpass Estimates
- Positive Sentiment: CRL raised its 2026 outlook to EPS of $11.15–$11.45 and revenue of roughly $3.9 billion, both ahead of analyst expectations. It also increased projected free cash flow to $400 million–$420 million. Charles River 2026 Outlook
- Positive Sentiment: Management cited improving biotech demand, stronger drug-discovery order trends and anticipated margin benefits from cost reductions and divestitures. The Discovery and Safety Assessment business reportedly has a healthy backlog and book-to-bill ratio. Charles River Lifts Profit Forecast
Institutional Trading of Charles River Laboratories International
Several large investors have recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its holdings in Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the period. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International in the first quarter worth $418,000. American Century Companies Inc. increased its position in Charles River Laboratories International by 41.9% in the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares during the last quarter. Brown Advisory Inc. boosted its holdings in Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after acquiring an additional 114 shares during the period. Finally, California Public Employees Retirement System boosted its stake in Charles River Laboratories International by 3.9% during the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after buying an additional 3,198 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.
About Charles River Laboratories International
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
